Cardiovascular medicine 1
Drug class to avoid during nitrate therapy
Phosphodiesterase-5 inhibitors
Initial nondrug therapy of acute SVT
Vagal maneuvers
Role of thrombolytic therapy in non–ST-elevation ACS
None
Primary CV side effect of bevacizumab
Hypertension
Leg pain at rest and skin ulceration
Critical limb ischemia
BP target for prevention of symptomatic HF
<130/80 mm Hg
Drugs to inhibit SVT induction and block AV conduction
β-Blockers and nondihydropyridine calcium channel blockers
Imaging method of choice to diagnose TAA
CT angiography
SVT with short PR interval and slurred QRS upstroke
Wolff-Parkinson-White syndrome
Imaging test for endocarditis and suspicion of myocardial abscess
TEE
First nonstatin options added to maximal statin therapy for secondary ASCVD prevention in patients at very high risk
Ezetimibe and/or PCSK9 monoclonal antibodies
Medical therapy for chronic aortic regurgitation and hypertension
Dihydropyridine calcium channel blockers, ACE inhibitors, or ARBs
Fever, myalgia, and respiratory symptoms followed by HF
Viral myocarditis
Diastolic opening snap and diastolic murmur at cardiac apex
Mitral stenosis
Concentric ventricular wall thickness with low QRS voltage
Cardiac amyloidosis
Management of TAA with diameter <5.0 cm
β-Blockers with target BP <130/80 mm Hg
Leading cause of death in patients with TAA
Ruptured aneurysm
Hypotension, back pain, and drop in hemoglobin level after femoral artery access for cardiac catheterization
Retroperitoneal hemorrhage
Treatment of PVC-induced cardiomyopathy
Catheter ablation
Biatrial enlargement; diastolic dysfunction; normal LV size, thickness, function
Restrictive cardiomyopathy
Three most common genetic conditions that require screening for aortic disease
Marfan, Ehlers-Danlos, and Turner syndromes
Disease-specific therapy for transthyretin amyloid cardiac amyloidosis
Tafamidis, acoramidis, vutrisiran
Indications for warfarin anticoagulation in moderate to severe mitral stenosis
Atrial fibrillation, left atrial thrombus, or systemic embolization
TEE criteria for severe aortic stenosis
Valve area ≤1.0 cm2, peak velocity ≥4 m/s, mean gradient ≥40 mm Hg
Impact of obesity on BNP levels
Lowers